How IFN-gamma helps the immune system fight leukemia after stem cell transplants
Mechanisms whereby IFN-gamma sensitizes AML to the graft-vs-leukemia effect
This study is looking at how a substance called IFN-gamma can help boost the immune system's ability to fight leukemia after a stem cell transplant, with the goal of finding better ways to treat patients with acute myeloblastic leukemia and similar blood cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10818349 on NIH RePORTER |
What this research studies
This research investigates the role of IFN-gamma in enhancing the immune response against leukemia cells following allogeneic hematopoietic stem cell transplantation (alloSCT). By studying mouse models of different types of leukemia, the researchers aim to understand why some leukemias are more resistant to the graft-vs-leukemia (GVL) effect than others. The study focuses on the intrinsic properties of leukemia cells that affect their sensitivity to immune attack, particularly looking at the signaling pathways involved. This could lead to improved strategies for using alloSCT to treat patients with acute myeloblastic leukemia and related conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with acute myeloblastic leukemia or those experiencing blast crisis chronic myelogenous leukemia.
Not a fit: Patients with other types of leukemia or those who are not candidates for stem cell transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for leukemia patients undergoing stem cell transplants, potentially reducing relapse rates.
How similar studies have performed: Previous research has shown that enhancing the GVL effect can improve outcomes in leukemia treatment, suggesting that this approach has potential for success.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Shlomchik, Warren D — University of Pittsburgh at Pittsburgh
- Study coordinator: Shlomchik, Warren D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.